A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Axogen, Inc. stock. As of the latest transaction made, Citadel Advisors LLC holds 40,100 shares of AXGN stock, worth $532,127. This represents 0.0% of its overall portfolio holdings.

Number of Shares
40,100
Previous 40,700 1.47%
Holding current value
$532,127
Previous $328,000 11.59%
% of portfolio
0.0%
Previous 0.0%

Shares

27 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

BUY
$5.67 - $8.06 $453,730 - $644,985
80,023 New
80,023 $579,000
Q4 2023

Feb 14, 2024

SELL
$3.61 - $7.76 $151,728 - $326,152
-42,030 Reduced 55.57%
33,598 $229,000
Q3 2023

Nov 14, 2023

SELL
$4.68 - $9.26 $227,841 - $450,813
-48,684 Reduced 39.16%
75,628 $378,000
Q2 2023

Aug 14, 2023

SELL
$8.5 - $10.38 $849,099 - $1.04 Million
-99,894 Reduced 44.55%
124,312 $1.13 Million
Q1 2023

May 15, 2023

SELL
$7.53 - $10.95 $223,475 - $324,974
-29,678 Reduced 11.69%
224,206 $2.12 Million
Q4 2022

Feb 14, 2023

BUY
$9.44 - $13.09 $2.14 Million - $2.97 Million
226,685 Added 833.43%
253,884 $2.53 Million
Q3 2022

Nov 14, 2022

SELL
$8.14 - $12.25 $1.49 Million - $2.24 Million
-182,754 Reduced 87.05%
27,199 $325,000
Q2 2022

Aug 15, 2022

SELL
$6.99 - $10.0 $1.44 Million - $2.05 Million
-205,368 Reduced 49.45%
209,953 $1.72 Million
Q1 2022

May 16, 2022

BUY
$7.26 - $10.7 $692,059 - $1.02 Million
95,325 Added 29.79%
415,321 $3.3 Million
Q4 2021

Feb 14, 2022

BUY
$8.8 - $16.0 $1.89 Million - $3.44 Million
215,112 Added 205.1%
319,996 $3 Million
Q3 2021

Nov 15, 2021

BUY
$15.23 - $21.72 $375,556 - $535,593
24,659 Added 30.74%
104,884 $1.66 Million
Q2 2021

Aug 16, 2021

SELL
$17.8 - $23.5 $464,152 - $612,786
-26,076 Reduced 24.53%
80,225 $1.73 Million
Q1 2021

May 17, 2021

BUY
$17.18 - $22.6 $998,982 - $1.31 Million
58,148 Added 120.76%
106,301 $2.15 Million
Q4 2020

Feb 16, 2021

BUY
$11.5 - $17.96 $177,134 - $276,637
15,403 Added 47.03%
48,153 $862,000
Q3 2020

Nov 16, 2020

BUY
$10.62 - $13.12 $347,805 - $429,680
32,750 New
32,750 $381,000
Q2 2020

Aug 14, 2020

SELL
$7.35 - $10.81 $690,157 - $1.02 Million
-93,899 Closed
0 $0
Q1 2020

May 15, 2020

SELL
$8.38 - $17.34 $935,618 - $1.94 Million
-111,649 Reduced 54.32%
93,899 $976,000
Q4 2019

Feb 14, 2020

BUY
$11.18 - $18.6 $1.93 Million - $3.22 Million
172,868 Added 528.97%
205,548 $3.68 Million
Q3 2019

Nov 14, 2019

BUY
$12.09 - $20.46 $264,601 - $447,787
21,886 Added 202.76%
32,680 $407,000
Q2 2019

Aug 14, 2019

SELL
$18.5 - $25.47 $989,916 - $1.36 Million
-53,509 Reduced 83.21%
10,794 $214,000
Q1 2019

May 15, 2019

SELL
$14.62 - $22.13 $580,501 - $878,693
-39,706 Reduced 38.18%
64,303 $0
Q4 2018

Feb 14, 2019

SELL
$17.09 - $38.25 $462,831 - $1.04 Million
-27,082 Reduced 20.66%
104,009 $2.12 Million
Q3 2018

Nov 13, 2018

BUY
$34.05 - $55.9 $3.36 Million - $5.52 Million
98,752 Added 305.37%
131,091 $0
Q2 2018

Aug 10, 2018

BUY
$36.15 - $52.5 $35,029 - $50,872
969 Added 3.09%
32,339 $0
Q1 2018

May 11, 2018

BUY
$24.4 - $40.25 $765,428 - $1.26 Million
31,370 New
31,370 $1.15 Million
Q4 2017

Feb 09, 2018

SELL
$18.5 - $28.6 $503,773 - $778,806
-27,231 Closed
0 $0
Q3 2017

Nov 09, 2017

BUY
$14.65 - $19.35 $398,934 - $526,919
27,231
27,231 $527,000

Others Institutions Holding AXGN

About Axogen, Inc.


  • Ticker AXGN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Medical Devices
  • Shares Outstandng 42,283,700
  • Market Cap $561M
  • Description
  • AxoGen, Inc., together with its subsidiaries, develops and markets surgical solutions for physical damage or transection to peripheral nerves. The company's products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed nerves without the comorbidities associated with a second surgic...
More about AXGN
Track Ken Griffin's Portfolio

Track Ken Griffin Portfolio

Follow Ken Griffin (Citadel Advisors LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.